Felicia Ceban1,2, Danica Nogo2, Isidro P Carvalho2, Yena Lee2, Flora Nasri2, Jiaqi Xiong2, Leanna M W Lui2, Mehala Subramaniapillai2,3, Hartej Gill2,3, Rene N Liu2, Prianca Joseph2, Kayla M Teopiz2, Bing Cao2, Rodrigo B Mansur2,4, Kangguang Lin5,6, Joshua D Rosenblat2,3,4, Roger C Ho7,8, Roger S McIntyre2,3,4. 1. Department of Immunology, University of Toronto, Toronto, Ontario, Canada. 2. Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, Ontario, Canada. 3. Braxia Health, Mississauga, Ontario, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 5. Department of Affective Disorders, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, China. 6. Laboratory of Emotion and Cognition, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, China. 7. Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 8. Institute for Health Innovation and Technology, National University of Singapore, Singapore.
Abstract
Importance: Preexisting noncommunicable diseases (eg, diabetes) increase the risk of COVID-19 infection, hospitalization, and death. Mood disorders are associated with impaired immune function and social determinants that increase the risk of COVID-19. Determining whether preexisting mood disorders represent a risk of COVID-19 would inform public health priorities. Objective: To assess whether preexisting mood disorders are associated with a higher risk of COVID-19 susceptibility, hospitalization, severe complications, and death. Data Sources: Systematic searches were conducted for studies reporting data on COVID-19 outcomes in populations with and without mood disorders on PubMed/MEDLINE, The Cochrane Library, PsycInfo, Embase, Web of Science, Google/Google Scholar, LitCovid, and select reference lists. The search timeline was from database inception to February 1, 2021. Study Selection: Primary research articles that reported quantitative COVID-19 outcome data in persons with mood disorders vs persons without mood disorders of any age, sex, and nationality were selected. Of 1950 articles identified through this search strategy, 21 studies were included in the analysis. Data Extraction and Synthesis: The modified Newcastle-Ottawa Scale was used to assess methodological quality and risk of bias of component studies. Reported adjusted odds ratios (ORs) were pooled with unadjusted ORs calculated from summary data to generate 4 random-effects summary ORs, each corresponding to a primary outcome. Main Outcomes and Measures: The 4 a priori primary outcomes were COVID-19 susceptibility, COVID-19 hospitalization, COVID-19 severe events, and COVID-19 death. The hypothesis was formulated before study search. Outcome measures between individuals with and without mood disorders were compared. Results: This review included 21 studies that involved more than 91 million individuals. Significantly higher odds of COVID-19 hospitalization (OR, 1.31; 95% CI, 1.12-1.53; P = .001; n = 26 554 397) and death (OR, 1.51; 95% CI, 1.34-1.69; P < .001; n = 25 808 660) were found in persons with preexisting mood disorders compared with those without mood disorders. There was no association between mood disorders and COVID-19 susceptibility (OR, 1.27; 95% CI, 0.73-2.19; n = 65 514 469) or severe events (OR, 0.94; 95% CI, 0.87-1.03; n = 83 240). Visual inspection of the composite funnel plot for asymmetry indicated the presence of publication bias; however, the Egger regression intercept test result was not statistically significant. Conclusions and Relevance: The results of this systematic review and meta-analysis examining the association between preexisting mood disorders and COVID-19 outcomes suggest that individuals with preexisting mood disorders are at higher risk of COVID-19 hospitalization and death and should be categorized as an at-risk group on the basis of a preexisting condition.
Importance: Preexisting noncommunicable diseases (eg, diabetes) increase the risk of COVID-19 infection, hospitalization, and death. Mood disorders are associated with impaired immune function and social determinants that increase the risk of COVID-19. Determining whether preexisting mood disorders represent a risk of COVID-19 would inform public health priorities. Objective: To assess whether preexisting mood disorders are associated with a higher risk of COVID-19 susceptibility, hospitalization, severe complications, and death. Data Sources: Systematic searches were conducted for studies reporting data on COVID-19 outcomes in populations with and without mood disorders on PubMed/MEDLINE, The Cochrane Library, PsycInfo, Embase, Web of Science, Google/Google Scholar, LitCovid, and select reference lists. The search timeline was from database inception to February 1, 2021. Study Selection: Primary research articles that reported quantitative COVID-19 outcome data in persons with mood disorders vs persons without mood disorders of any age, sex, and nationality were selected. Of 1950 articles identified through this search strategy, 21 studies were included in the analysis. Data Extraction and Synthesis: The modified Newcastle-Ottawa Scale was used to assess methodological quality and risk of bias of component studies. Reported adjusted odds ratios (ORs) were pooled with unadjusted ORs calculated from summary data to generate 4 random-effects summary ORs, each corresponding to a primary outcome. Main Outcomes and Measures: The 4 a priori primary outcomes were COVID-19 susceptibility, COVID-19 hospitalization, COVID-19 severe events, and COVID-19 death. The hypothesis was formulated before study search. Outcome measures between individuals with and without mood disorders were compared. Results: This review included 21 studies that involved more than 91 million individuals. Significantly higher odds of COVID-19 hospitalization (OR, 1.31; 95% CI, 1.12-1.53; P = .001; n = 26 554 397) and death (OR, 1.51; 95% CI, 1.34-1.69; P < .001; n = 25 808 660) were found in persons with preexisting mood disorders compared with those without mood disorders. There was no association between mood disorders and COVID-19 susceptibility (OR, 1.27; 95% CI, 0.73-2.19; n = 65 514 469) or severe events (OR, 0.94; 95% CI, 0.87-1.03; n = 83 240). Visual inspection of the composite funnel plot for asymmetry indicated the presence of publication bias; however, the Egger regression intercept test result was not statistically significant. Conclusions and Relevance: The results of this systematic review and meta-analysis examining the association between preexisting mood disorders and COVID-19 outcomes suggest that individuals with preexisting mood disorders are at higher risk of COVID-19 hospitalization and death and should be categorized as an at-risk group on the basis of a preexisting condition.
Authors: Faith Dickerson; Jennifer Schroeder; Emily Katsafanas; Sunil Khushalani; Andrea E Origoni; Christina Savage; Lucy Schweinfurth; Catherine R Stallings; Kevin Sweeney; Robert H Yolken Journal: Psychiatr Serv Date: 2017-09-15 Impact factor: 3.084
Authors: Eric J Lenze; Caline Mattar; Charles F Zorumski; Angela Stevens; Julie Schweiger; Ginger E Nicol; J Philip Miller; Lei Yang; Michael Yingling; Michael S Avidan; Angela M Reiersen Journal: JAMA Date: 2020-12-08 Impact factor: 56.272
Authors: Ahmad A Toubasi; Rand B AbuAnzeh; Hind B Abu Tawileh; Renad H Aldebei; Saif Aldeen S Alryalat Journal: Psychiatry Res Date: 2021-03-03 Impact factor: 11.225
Authors: Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683
Authors: Borja Pedruzo; Ana Catalan; Claudia Aymerich; Marta Bordenave; Olatz Estevez; Diego Aurofio Gómez; Jon Herrero; María Laborda; Gonzalo Mancebo; Ania Martínez; Malein Pacho; Ana Paniagua; José Luis Pérez; Miguel Ángel González-Torres Journal: Rev Psiquiatr Salud Ment Date: 2022-06-17 Impact factor: 6.795
Authors: Bruno Faustino; António Branco Vasco; João Delgado; António Farinha-Fernandes; José Carlos Guerreiro Journal: Clin Psychol Psychother Date: 2022-01-17
Authors: Seyedmohammad Mirhosseini; Samuel Grimwood; Ali Dadgari; Mohammad Hasan Basirinezhad; Rasoul Montazeri; Hossein Ebrahimi Journal: Health Sci Rep Date: 2022-01-12
Authors: Christoph U Correll; Craig Chepke; Paul Gionfriddo; Joe Parks; Phyllis Foxworth; Anirban Basu; Teri S Brister; Dawn Brown; Christopher Clarke; Youssef Hassoun Journal: BMC Psychiatry Date: 2022-01-10 Impact factor: 3.630